23andMe Investor Presentation Deck

We Are Redefining Healthcare. With Data. At Scale. Cumulative Genotyped Customers (in M, fiscal year ends March 31) 2.0 FY17A 4.4 FY18A 7.8 FY19A 10M+ Genetic Profiles Created Critical Mass 9.8 FY20A ¹As of December 31, 2021. 2As of March 31, 2021. Programs include collaborated, 100% owned and royalty interest targets. 11.3 FY21A 12.2 FY22Q3 Empowering Consumers 12.2M Genotyped Customers¹ Enabling Research & Services 4B+ Phenotypic Data Points² Developing Therapeutics 40+ Programs² Copyright © 2022 23and Me, Inc. 23andMe 11

View entire presentation